Why Mesoblast Limited (MESO) is One of the Best Low Priced Biotech Stocks to Invest in
Mesoblast Limited (NASDAQ:MESO) is one of the best low priced biotech stocks to invest in.
Mesoblast Ltd (MESO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 468,100 | $8,444,524 | +104% | 0% | |
| 2. | Citadel Investment Group Ken Griffin | 131,388 | $2,370,240 | 0% | |
| 3. | 50,000 | $902,000 | 0% | ||
| 4. | Point72 Asset Management Steve Cohen | 38,185 | $688,857 | 0% | |
| 5. | 31,100 | $561,044 | -53% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.48 | 2,324,072 | $3,439,626.56 | 8,324,072 | 2026-04-10 | Filing | |
| $1.41 | 10,000 | $14,100.00 | 13,586,890 | 2026-04-09 | Filing | |
| $1.43 | 10,000 | $14,300.00 | 13,576,890 | 2026-04-09 | Filing | |
| $1.43 | 10,000 | $14,300.00 | 13,566,890 | 2026-04-09 | Filing | |
| $1.43 | 5,000 | $7,150.00 | 13,556,890 | 2026-04-09 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 87,075 | $1,339,213 | 1.01% | |
| 2. | 46,121 | $709,341 | 0.25% | |
| 3. | 16,000 | $246,080 | 0.07% | |
| 4. | 6,544 | $100,647 | 0% | |
| 5. | 6,497 | $99,924 | 0% |
News See All
8 Best Long-Term ASX Stocks to Buy Right Now
Based on Reuters’ report dated April 14, 2026, consumer sentiment in Australia has softened significantly, as highlighted by the Westpac-Melbourne Institute Index’s 12.5% drop to 80.1 in April, its...
8 Best Low Priced Biotech Stocks to Invest In
On April 16, Fundstrat’s Tom Lee appeared on CNBC's 'Closing Bell' to talk about what to expect from equity markets going forward.
Mesoblast Limited (NASDAQ:MESO) Q2 2026 Earnings Call Transcript
Operator: Hello, and welcome to the Mesoblast financial results for the half year ended December 31, 2025.
Mesoblast (MESO) Sees Optimism From Analysts
Mesoblast Limited (NASDAQ:MESO) is a biotechnology company developing treatments for inflammatory diseases, heart failure, and other ailments.
7 Best ASX Stocks to Buy Right Now
While the Federal Reserve cut interest rates in the US a couple of days back, in Australia, the trend appears to be moving in the opposite direction.
Mesoblast's Ryoncil Gains Permanent CMS J-Code for Billing and Reimbursement
Mesoblast Limited (NASDAQ:MESO) is one of the best hot stocks to invest in.
12 Best Hot Stocks to Invest In
On September 24, Ryan Detrick, Carson Group chief market strategist, joined CNBC's 'Power Lunch' to discuss why he still expects a strong end-of-year rally.
Mesoblast Limited (MESO)’s Ryoncil® Gains U.S.-Origin Status, Avoids Import Tariffs
Mesoblast Limited (NASDAQ:MESO) is a global leader in developing allogeneic, off-the-shelf cellular medicines for inflammatory diseases.
12 Healthcare Stocks with Insider Buying in 2025
In 2025, there will be a complicated combination of opportunities and difficulties in the healthcare innovation landscape, with divergent trends in technology adoption, investment, and fundraising.
Hedge Fund Resource Center